Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T15:30:28.227Z Has data issue: false hasContentIssue false
  • English
  • Français

Function of Cholinergic Circuits and Detection of Impairment

Published online by Cambridge University Press:  07 November 2014

Gary Kay
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
CME-Accredited Roundtable Monograph
Information
CNS Spectrums , Volume 9 , Issue 12 , December 2004 , pp. 2 - 4
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Volpicelli, LA, Levey, AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res. 2004;145:59–66.Google Scholar
2.Coyle, JT, Price, DL, DeLong, MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1083; 219:1184–1190.Google Scholar
3.Wess, J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol. 2004;44:423–450.Google Scholar
4.Tzavara, ET, Bymaster, FP, Felder, CC, et al.Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4, and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry. 2003;8:673–679.Google Scholar
5.Zhang, W, Basile, AS, Gomeza, J, et al.Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci. 2002;22(5):1709–1717.Google Scholar
6.Bartus, R, Dean, RL 3rd, Beer, B, Lippa, AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414.Google Scholar
7.Cummings, JL. Alzheimer's disease. N Eng J Med. 2004;351:56–67.Google Scholar
8.Diefenbach, K, Donath, F, Maurer, A, et al.Randomized, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Invest. 2003;23:395–404.Google Scholar
9.Katz, IR, Sands, LP, Bilker, W, et al.Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13.Google Scholar
10.Kay, G. The M3 selective receptor antagonist darifenacin has no clinically relevant effect on cognition and cardiac function [abstract]. Prog Urol. 2004;14:22. Abstract 65.Google Scholar
11.Wesnes, K, Lipton, R, Kolodner, K, Edgar, C. Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur Urol Suppl. 2004;3:A513.Google Scholar